Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 3
2007 3
2008 3
2009 5
2010 3
2011 1
2012 1
2013 6
2014 10
2015 4
2016 9
2017 13
2018 9
2019 19
2020 17
2021 27
2022 19
2023 19
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
Skeletal muscle of young females under resistance exercise exhibits a unique innate immune cell infiltration profile compared to males and elderly individuals.
Castrogiovanni P, Sanfilippo C, Imbesi R, Lazzarino G, Li Volti G, Tibullo D, Vicario N, Parenti R, Giuseppe L, Barbagallo I, Alanazi AM, Vecchio M, Cappello F, Musumeci G, Di Rosa M. Castrogiovanni P, et al. Among authors: vecchio m. J Muscle Res Cell Motil. 2024 Apr 5. doi: 10.1007/s10974-024-09668-6. Online ahead of print. J Muscle Res Cell Motil. 2024. PMID: 38578562
Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.
Muraro E, Montico B, Lum B, Colizzi F, Giurato G, Salvati A, Guerrieri R, Rizzo A, Comaro E, Canzonieri V, Anichini A, Del Vecchio M, Mortarini R, Milione M, Weisz A, Pizzichetta MA, Simpson F, Dolcetti R, Fratta E, Sigalotti L. Muraro E, et al. Among authors: del vecchio m. Front Immunol. 2024 Mar 6;15:1336566. doi: 10.3389/fimmu.2024.1336566. eCollection 2024. Front Immunol. 2024. PMID: 38510242 Free PMC article.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
Schadendorf D, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak A, Del Vecchio M, de la Cruz-Merino L, Mackiewicz J, Sileni VC, Kirkwood JM, Robert C, Grob JJ, Dummer R, Carlino MS, Zhao Y, Kalabis M, Krepler C, Eggermont A, Scolyer RA. Schadendorf D, et al. Among authors: del vecchio m. J Immunother Cancer. 2024 Mar 13;12(3):e007501. doi: 10.1136/jitc-2023-007501. J Immunother Cancer. 2024. PMID: 38485189 Free PMC article. Clinical Trial.
Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531].
Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P, Guidoboni M, Marchetti P, Simonetti E, Santangelo F, Amato G, Covre A, Camerini R, Valente M, Mandalà M, Giannarelli D, Calabrò L, Maio M. Di Giacomo AM, et al. Among authors: del vecchio m. Eur J Cancer. 2024 May;202:113981. doi: 10.1016/j.ejca.2024.113981. Epub 2024 Mar 9. Eur J Cancer. 2024. PMID: 38461074 No abstract available.
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Luke JJ, et al. Among authors: del vecchio m. J Clin Oncol. 2024 Mar 7:JCO2302355. doi: 10.1200/JCO.23.02355. Online ahead of print. J Clin Oncol. 2024. PMID: 38452313
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
Kirkwood JM, Vecchio MD, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: vecchio md. Future Oncol. 2024 May;20(15):959-968. doi: 10.2217/fon-2023-0977. Epub 2024 Feb 23. Future Oncol. 2024. PMID: 38390818 Free article. Review.
Damage for gain: The useful damage of the Pitcher's paradox.
Chiaramonte R, Testa G, Russo A, Buccheri E, Milana M, Prezioso R, Pavone V, Vecchio M. Chiaramonte R, et al. Among authors: vecchio m. Heliyon. 2024 Feb 1;10(3):e25401. doi: 10.1016/j.heliyon.2024.e25401. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38327463 Free PMC article.
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P, Guidoboni M, Marchetti P, Simonetti E, Santangelo F, Amato G, Covre A, Camerini R, Valente M, Mandalà M, Giannarelli D, Calabrò L, Maio M. Di Giacomo AM, et al. Among authors: del vecchio m. Eur J Cancer. 2024 Mar;199:113531. doi: 10.1016/j.ejca.2024.113531. Epub 2024 Jan 11. Eur J Cancer. 2024. PMID: 38271746 Free article. Clinical Trial.
169 results